Deepak L. Bhatt, MD, MPH, FACC

Deepak Bhatt

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Elsevier Practice Update Cardiology(SIGNIFICANT) OFFICER, DIRECTOR ETC: TobeSoft(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Eisai(SIGNIFICANT), FlowCo(NONE), Roche(SIGNIFICANT), Sanofi Aventis(SIGNIFICANT), PLx Pharma(NONE), Bristol Myers Squibb(SIGNIFICANT), Takeda(NONE), Pfizer Inc(SIGNIFICANT), Forest Laboratories(SIGNIFICANT), Amarin(SIGNIFICANT), Astra Zeneca(SIGNIFICANT), Medtronic(SIGNIFICANT), Ethicon(SIGNIFICANT), Ischemix(SIGNIFICANT), The Medicines Company(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Chiesi(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Ironwood(SIGNIFICANT), Abbott(SIGNIFICANT), Regeneron(SIGNIFICANT), PhaseBio(SIGNIFICANT), Idorsia(SIGNIFICANT), Synaptic(SIGNIFICANT) OTHER FINANCIAL BENEFIT: WebMD(SIGNIFICANT), Medscape Cardiology(NONE), Regado Biosciences(NONE), Cardax(NONE), Merck & Co., Inc.(NONE), Elsevier(MODEST), Journal of Invasive Cardiology(SIGNIFICANT), Belvoir Publications(SIGNIFICANT), Clinical Cardiology(NONE), Slack Publications/Cardiology Research Foundation(SIGNIFICANT), HMP Global(SIGNIFICANT)

View Full Disclosure